Opportunity Information: Apply for PAR 11 256
Apply for PAR 11 256
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Pre Application for the FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (X02)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Jul 29, 2011 and posted on Jul 29, 2011.
- Applicants must submit their applications by Nov 30, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses Special district governments Native American tribal governments (Federally recognized) County governments Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments City or township governments Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign (non U.S.) components of U.S. Organizations are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Pre-Application for the FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (X02) is a National Institutes of Health opportunity (Funding Opportunity Number PAR 11-256) designed to identify and support individual scientists who can bring unusually creative, high-risk, high-reward ideas to HIV/AIDS research in the specific context of drug abuse. The program is framed around the concept of "avant garde" work, meaning proposals are expected to be genuinely transformative rather than incremental. The emphasis is on research that could open entirely new lines of inquiry or create fresh prevention and treatment strategies for HIV/AIDS among people who use drugs, particularly where drug use intersects with transmission risk, disease progression, and care outcomes.
A defining feature of this opportunity is its insistence on novelty that goes beyond an investigator's existing trajectory and beyond what is already common in the field. In practical terms, the proposed project should not look like a natural next step from prior work or a modest variation on established approaches. Instead, it should introduce substantially different ideas, methods, or conceptual frameworks that can shift how researchers understand or address HIV/AIDS in drug-using populations. The research scope must also align with priorities laid out in the Trans-NIH Plan for HIV-Related Research (linked in the announcement), which serves as the broader strategic roadmap across NIH for HIV research areas and goals. Applicants are therefore expected to anchor their innovation within those trans-NIH priorities, showing both originality and relevance to nationally defined HIV research needs.
This posting describes a pre-application mechanism (X02), which generally functions as an initial step intended to surface the most promising, boundary-pushing concepts before full applications are invited or advanced. While the announcement text provided here does not list budget levels or project periods, it clearly positions the program as a discretionary grant opportunity focused on high-impact scientific leadership and unconventional approaches with the potential for real-world benefit in prevention or treatment among drug-abusing populations. There is no cost sharing or matching requirement, which reduces barriers for applicants who may not have institutional resources to contribute additional funding.
Eligibility is broad and deliberately inclusive, spanning many types of domestic and international institutions and organizations. Eligible applicants include public and private institutions of higher education; nonprofits both with and without 501(c)(3) status; for-profit organizations (including small businesses and other than small businesses); local, county, state, tribal, and special district governments; independent school districts; and public housing authorities/Indian housing authorities. The eligibility language explicitly includes institutions and organizations that often serve underrepresented or priority communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations. The opportunity also allows non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and foreign components of U.S. organizations, signaling that NIDA is open to globally relevant expertise and cross-border collaborations when they strengthen the scientific premise and impact.
Administratively, the opportunity falls under the NIH umbrella with the CFDA listing 93.279 (Drug Abuse and Addiction Research Programs), aligning it with NIDA's mission to advance science on drug use and its consequences. The announcement was posted and created on July 29, 2011, with an original and current closing date of November 30, 2011, and an archive date of December 31, 2011. Applicants were directed to the full funding announcement via the NIH Grants Guide link provided, and NIH offered technical contact support through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Overall, this grant pre-application opportunity targets standout investigators willing to propose bold, unconventional HIV/AIDS research ideas directly connected to drug abuse contexts, with the explicit goal of catalyzing new directions that could meaningfully improve prevention and treatment outcomes. The central message is that the program is not looking for safe, incremental science; it is looking for proposals that can plausibly change the landscape of HIV/AIDS research and intervention for populations affected by drug use, while staying grounded in the strategic priorities laid out in the Trans-NIH HIV research plan.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is the Pre-Application for the FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (X02), a National Institutes of Health (NIH) opportunity with Funding Opportunity Number PAR 11-256. It is intended to identify and support individual scientists proposing unusually creative, high-risk, high-reward ideas for HIV/AIDS research specifically in the context of drug abuse.
What does "Avant Garde" mean in this program?
"Avant garde" signals that the program is seeking genuinely transformative concepts rather than incremental advances. Proposals are expected to push beyond standard approaches and plausibly change how HIV/AIDS is understood, prevented, or treated among people who use drugs.
Is this a full grant application or an initial step?
This posting describes a pre-application mechanism (X02). It generally functions as an initial step to surface the most promising boundary-pushing concepts before full applications are invited or advanced.
What research focus is required?
The research must address HIV/AIDS in the specific context of drug abuse. The emphasis is on work that can open new lines of inquiry or create new prevention and treatment strategies for HIV/AIDS among people who use drugs, including where drug use intersects with HIV transmission risk, disease progression, and care outcomes.
How novel does the proposed research need to be?
The opportunity emphasizes novelty that goes beyond the investigator's existing trajectory and beyond what is already common in the field. The project should not look like a natural next step from prior work or a modest variation on established approaches; it should introduce substantially different ideas, methods, or conceptual frameworks.
Does the proposal need to align with any NIH-wide priorities?
Yes. The research scope must align with priorities described in the Trans-NIH Plan for HIV-Related Research referenced in the announcement. Applicants are expected to connect their innovation to those trans-NIH priorities while demonstrating originality and relevance to national HIV research needs.
What kind of impact is NIDA looking for?
NIDA is looking for high-impact scientific leadership and unconventional approaches with the potential for real-world benefit in HIV prevention or treatment among drug-abusing populations. The central theme is catalyzing new directions that could meaningfully improve outcomes.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
Who is eligible to apply?
Eligibility is broad and includes many types of domestic and international institutions and organizations. Eligible applicants include public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; for-profit organizations (including small businesses and other than small businesses); local, county, state, tribal, and special district governments; independent school districts; and public housing authorities/Indian housing authorities.
Are organizations serving underrepresented communities explicitly included?
Yes. The eligibility language explicitly includes Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations.
Can non-U.S. organizations apply?
Yes. The opportunity allows non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and foreign components of U.S. organizations.
What is the associated CFDA number and NIH program area?
The opportunity is listed under CFDA 93.279 (Drug Abuse and Addiction Research Programs), aligning it with NIDA's mission to advance science on drug use and its consequences.
What are the key dates for this opportunity?
The announcement was posted and created on July 29, 2011. The original and current closing date is November 30, 2011. The archive date is December 31, 2011.
Where can applicants find the full funding announcement?
Applicants were directed to the full funding announcement through the NIH Grants Guide link provided in the announcement.
Who should be contacted for technical issues accessing the announcement?
NIH offered technical contact support through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Does the provided information specify budget levels or project periods?
No. The text provided does not list budget levels or project periods.
What is the overall goal of the X02 pre-application opportunity?
The overall goal is to identify standout investigators who will propose bold, unconventional HIV/AIDS research ideas tied directly to drug abuse contexts, with the intent of catalyzing new directions and improving prevention and treatment outcomes for populations affected by drug use.
What types of proposals are discouraged by the program emphasis?
The emphasis discourages safe, incremental science, including projects that are modest variations on established approaches or that read as a predictable next step from an investigator's existing work.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1)
Previous opportunity: Pre Application for the 2012 NIDA Translational Avant Garde Award for Medication Development for the Treatment of Substance Use Disorders (X02)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 11 256
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 11 256) also looked into and applied for these:
| Funding Opportunity |
|---|
| FY12 NIDA Avant Garde Award Program for HIV/AIDS Research (DP1) Apply for RFA DA 12 011 Funding Number: RFA DA 12 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Centers of Biomedical Research Excellence (COBRE) (P20) Apply for PAR 11 286 Funding Number: PAR 11 286 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Pilot studies in Pancreatic Cancer (R21) Apply for PA 11 297 Funding Number: PA 11 297 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Pilot studies in Pancreatic Cancer (R03) Apply for PA 11 298 Funding Number: PA 11 298 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Drug Abuse Prevention Intervention Research (R03) Apply for PA 11 313 Funding Number: PA 11 313 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Drug Abuse Prevention Intervention Research (R01) Apply for PA 11 311 Funding Number: PA 11 311 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Prevention Intervention Research (R21) Apply for PA 11 312 Funding Number: PA 11 312 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Human Health and Heredity in Africa (H3Africa) Research Grants (U01) Apply for RFA RM 11 009 Funding Number: RFA RM 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Scalable Assays for Unbiased In Vitro Analysis of Neurobiological Function (R21/R33) Apply for PAR 11 319 Funding Number: PAR 11 319 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions (R21) Apply for RFA CA 11 012 Funding Number: RFA CA 11 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Research Answers to NCIs Provocative Questions (R01) Apply for RFA CA 11 011 Funding Number: RFA CA 11 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R03) Apply for PA 11 331 Funding Number: PA 11 331 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R01) Apply for PA 11 330 Funding Number: PA 11 330 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools to Promote Effective PatientProvider Communication, Adherence to Treatment and Self Management of Chronic Diseases In Underserved Populations (R21) Apply for PA 11 332 Funding Number: PA 11 332 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Scholars Training for the Advancement of Research (STAR) Competitive Revision to NINR T32 Training Grants (T32) Apply for RFA NR 11 011 Funding Number: RFA NR 11 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of novel and emerging technologies for the accurate detection and diagnosis of polymicrobial infections in biomedical laboratory animal models (SBIR R43/R44) Apply for PA 11 340 Funding Number: PA 11 340 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development of Novel and Emerging Technologies for the Accurate Detection and Diagnosis of Polymicrobial Infections in Biomedical Laboratory Animal Models (STTR R41/R42) Apply for PA 11 341 Funding Number: PA 11 341 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Research Network a Research Resource within Health Care Delivery System (Limited Competition U24) Apply for RFA CA 11 502 Funding Number: RFA CA 11 502 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| National Cancer Institute Program Project (P01) Applications Apply for PAR 12 005 Funding Number: PAR 12 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 12 001 Funding Number: RFA CA 12 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 11 256", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.